Drug search by name

AccessPak for HIV PEP Expanded with Viracept and Delavirdine

Determining the interaction of AccessPak for HIV PEP Expanded with Viracept and Delavirdine and the possibility of their joint administration.

Check result:

AccessPak for HIV PEP Expanded with Viracept <> Delavirdine

Relevance: 23.03.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using nelfinavir together with delavirdine may increase the effects of nelfinavir. Contact your doctor if you experience nausea, vomiting, diarrhea, increased urination or extreme thirst, easy bruising or bleeding, or signs of a new infection, such as fever or chills, cough, or flu symptoms. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor

Professional:

MONITOR: Coadministration with delavirdine may significantly increase the plasma concentrations of nelfinavir. The mechanism is delavirdine inhibition of nelfinavir metabolism via CYP450 3A4 and 2C19. According to the delavirdine labeling, coadministration of delavirdine (400 mg three times a day) and nelfinavir (750 mg three times a day) for 7 days increased the mean peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and trough plasma concentration (Cmin) of nelfinavir by 88%, 107% and 136%, respectively, compared to administration of nelfinavir alone. Plasma concentrations of the active metabolite, nelfinavir hydroxy-t-butylamide, were significantly reduced but were more than compensated for by the increased nelfinavir concentration. Delavirdine Cmax, AUC and Cmin decreased by 27%, 31% and 33%, respectively.

MANAGEMENT: Appropriate dosages for the combination of nelfinavir and delavirdine with respect to safety and efficacy have not been established. Patients should be monitored for toxicity such as elevations in liver function tests, neutropenia, and undue gastrointestinal disturbances, especially diarrhea.

References

Developed by the panel of Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: URL: http://AIDSinfo.nih.gov." ([2003 Nov 10]):
"Product Information. Rescriptor (delavirdine)." Pharmacia and Upjohn, Kalamazoo, MI.

AccessPak for HIV PEP Expanded with Viracept

Generic Name: emtricitabine / nelfinavir / tenofovir

Brand name: AccessPak for HIV PEP Expanded with Viracept

Synonyms: n.a.

What is AccessPak for HIV PEP Expanded with Viracept?

Delavirdine

Generic Name: delavirdine

Brand name: Rescriptor

Synonyms: n.a.

What is Delavirdine?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions